ReviewmBio2016
How Can Vaccines Contribute to Solving the Antimicrobial Resistance Problem?
Review in mBio, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
113 citing papers in PubMed, 5 syntheses or guidelines pooled it, 217 citations in OpenAlex.
- The impact of the introduction of ten- or thirteen-valent pneumococcal conjugate vaccines on antimicrobial-resistant pneumococcal disease and carriage: A systematic literature review.Journal of global health · 2023Pooled it
- Antimicrobial resistance in paediatricThe Lancet. Microbe · 2021Pooled it
- The direct and indirect effects of the pneumococcal conjugated vaccine on carriage rates in children aged younger than 5 years in Latin America and the Caribbean: a systematic review.Einstein (Sao Paulo, Brazil) · 2020Pooled it
- Population-level mathematical modeling of antimicrobial resistance: a systematic review.BMC medicine · 2019Pooled it
- Towards a global definition of responsible antibiotic use: results of an international multidisciplinary consensus procedure.The Journal of antimicrobial chemotherapy · 2018Pooled it
- Prevention of antimicrobial prescribing among infants following maternal vaccination against respiratory syncytial virus.Proceedings of the National Academy of Sciences of the United States of America · 2022Trial
- Antimicrobial Resistance at the Human-Animal-Environment Interface: A One Health Perspective on Drivers, Transmission, and Public Health Responses.Health science reports · 2026Article
- Immunotherapeutic modalities for combating multidrug-resistant bacteria: therapeutic promises of antibodies and next-generation vaccines.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Review
- [Use of vaccines to prevent the development of bacterial resistance].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2026Review
- Disease-Causing Mechanisms and Therapeutic Targets in Infectious Diseases: Implications for Clinical Management and Public Health.Biomedicines · 2026Review
- Pediatric Pneumococcal Eye Infection and Changes in Antibiotic Susceptibility: A Retrospective Study.Infection & chemotherapy · 2026Article
- Article
- The sero-prevalence and virulence determinants ofMicrobiology spectrum · 2026Article
- The Public Health Risks of Colistin Resistance in Dogs and Cats: A One Health Perspective Review.Antibiotics (Basel, Switzerland) · 2025Review
- Conceptual Methodological Framework for Incorporating Antimicrobial Resistance Considerations in Economic Models for Pneumococcal Conjugate Vaccines.Infectious diseases and therapy · 2025Article
- No innocent bystanders: pertussis vaccination and evolutionary parallelisms betweenMicrobial genomics · 2025Article
- The Central Importance of Vaccines to Mitigate the Threat of Antibiotic-Resistant Bacterial Pathogens.Vaccines · 2025Review
- NovelmBio · 2025Article
- 'When global health meets global goals': assessing the alignment between antimicrobial resistance and sustainable development policies in 10 African and Asian countries.BMJ global health · 2025Article
53 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
There is a growing appreciation for the role of vaccines in confronting the problem of antimicrobial resistance (AMR). Vaccines can reduce the prevalence of resistance by reducing the need for antimicrobial use and can reduce its impact by reducing the total number of cases. By reducing the number of pathogens that may be responsible for a particular clinical syndrome, vaccines can permit the use of narrower-spectrum antibiotics for empirical therapy. These effects may be amplified by herd immunity, extending protection to unvaccinated persons in the population. Because much selection for resistance is due to selection on bystander members of the normal flora, vaccination can reduce pressure for resistance even in pathogens not included in the vaccine. Some vaccines have had disproportionate effects on drug-resistant lineages within the target species, a benefit that could be more deliberately exploited in vaccine design. We describe the effects of current vaccines in controlling AMR, survey some vaccines in development with the potential to do so further, and discuss strategies to amplify these benefits. We conclude with a discussion of research and policy priorities to more fully enlist vaccines in the battle against AMR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.